Evidence map›Paper›PMID 33392080›Full record

ArticleFrontiers in oncology2020

Prognostic Role of ABO Blood Type in Operable Esophageal Cancer: Analysis of 2179 Southern Chinese Patients.

Shuishen Zhang, Minghan Jia, Xiaoli Cai, Weixiong Yang, Shufen Liao, Zhenguo Liu, Jing Wen, Kongjia Luo, Chao Cheng

Abstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuishen ZhangDepartment of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Minghan JiaDepartment of Breast Cancer, Guangdong Provincial People's Hospital Cancer Center, Guangdong Academy of Medical Sciences, Guangzhou, China.
Xiaoli CaiDepartment of Medical Ultrasonics, First Affiliated Hospital of Jinan University, Guangzhou, China.
Weixiong YangDepartment of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Shufen LiaoOperating room of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zhenguo LiuDepartment of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jing WenGuangdong Esophageal Cancer Institute, Guangzhou, China.
Kongjia LuoGuangdong Esophageal Cancer Institute, Guangzhou, China.
Chao ChengDepartment of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC.

methodsThis study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models.

resultsUnivariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS (

conclusionsThe results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.

Indexed as

ABO blood groupesophageal cancerlarge cohortprognostic factorsurvival

Identifiers

PMID33392080
PMCPMC7775654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.